Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening
Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec’2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vacc...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | Tumour Virus Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666679023000022 |
| _version_ | 1797812749657440256 |
|---|---|
| author | Louiza S. Velentzis David Hawkes Michael Caruana Julia ML. Brotherton Megan A. Smith Lara Roeske Khurram A. Karim Suzanne M. Garland C. David Wrede Jeffery Tan Cosette Wheeler Philip E. Castle Marion Saville Karen Canfell |
| author_facet | Louiza S. Velentzis David Hawkes Michael Caruana Julia ML. Brotherton Megan A. Smith Lara Roeske Khurram A. Karim Suzanne M. Garland C. David Wrede Jeffery Tan Cosette Wheeler Philip E. Castle Marion Saville Karen Canfell |
| author_sort | Louiza S. Velentzis |
| collection | DOAJ |
| description | Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec’2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005–2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA). Post-vaccination samples (2013-2014) (n = 2989; Compass pilot), from 25 to 64-year-old women, were analysed by cobas 4800 (cobas), and by LA for historical comparability. Age standardised pre-vaccination HPV16/18 prevalence was 4.85% (95%CI:3.81–5.89) by LA; post-vaccination estimates were 1.67% (95%CI:1.21–2.13%) by LA, 1.49% (95%CI:1.05–1.93%) by cobas, and 1.63% (95%CI:1.17–2.08%) for cobas and LA testing of non-16/18 cobas positives (cobas/LA). Age-standardised pre-vaccination oncogenic HPV prevalence was 15.70% (95%CI:13.79–17.60%) by LA; post-vaccination estimates were 9.06% (95%CI:8.02–10.09%) by LA, 8.47% (95%CI:7.47–9.47%) by cobas and cobas/LA. Standardised rate ratios between post-vs. pre-vaccination rates were significantly different for HPV16/18, non-16/18 HPV and oncogenic HPV: 0.34 (95%CI:0.23–0.50), 0.68 (95%CI:0.55–0.84) and 0.58 (95%CI:0.48–0.69), respectively. Additional strategies (LA for all cobas positives; combined cobas and LA results on all samples) had similar results. If a single method is applied consistently, it will provide important data on relative changes in HPV prevalence following vaccination. |
| first_indexed | 2024-03-13T07:43:05Z |
| format | Article |
| id | doaj.art-b14dd6b43e0b4bb8a9aa153c7078c67d |
| institution | Directory Open Access Journal |
| issn | 2666-6790 |
| language | English |
| last_indexed | 2024-03-13T07:43:05Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Tumour Virus Research |
| spelling | doaj.art-b14dd6b43e0b4bb8a9aa153c7078c67d2023-06-03T04:22:47ZengElsevierTumour Virus Research2666-67902023-06-0115200255Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screeningLouiza S. Velentzis0David Hawkes1Michael Caruana2Julia ML. Brotherton3Megan A. Smith4Lara Roeske5Khurram A. Karim6Suzanne M. Garland7C. David Wrede8Jeffery Tan9Cosette Wheeler10Philip E. Castle11Marion Saville12Karen Canfell13The Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, Australia; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; Corresponding author. The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling Street, Woolloomooloo, NSW 2011, AustraliaAustralian Centre for the Prevention of Cervical Cancer, 265 Faraday Street, Carlton South, Victoria, Australia; Department of Biochemistry and Pharmacology, University of Melbourne, Victoria, Australia; Department of Pathology, University of Malaya, Kuala Lumpur, MalaysiaThe Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, AustraliaMelbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; Australian Centre for the Prevention of Cervical Cancer, 265 Faraday Street, Carlton South, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Malaya, Kuala Lumpur 50603, MalaysiaThe Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, AustraliaRoyal Australian College of General Practitioners, East Melbourne, Victoria, AustraliaAustralian Centre for the Prevention of Cervical Cancer, 265 Faraday Street, Carlton South, Victoria, AustraliaInfection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia; Centre Women's Infectious Diseases Research, Royal Women's Hospital, Melbourne, Victoria, AustraliaDepartment of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia; Department of Oncology & Dysplasia, Royal Women's Hospital, Melbourne, Victoria, AustraliaDepartment of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia; Department of Oncology & Dysplasia, Royal Women's Hospital, Melbourne, Victoria, AustraliaUniversity of New Mexico Cancer Center, Albuquerque, NM, USADivision of Cancer Prevention, National Cancer Institute, NIH, Rockville, MD, USA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USAAustralian Centre for the Prevention of Cervical Cancer, 265 Faraday Street, Carlton South, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Malaya, Kuala Lumpur 50603, MalaysiaThe Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, AustraliaAustralia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec’2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005–2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA). Post-vaccination samples (2013-2014) (n = 2989; Compass pilot), from 25 to 64-year-old women, were analysed by cobas 4800 (cobas), and by LA for historical comparability. Age standardised pre-vaccination HPV16/18 prevalence was 4.85% (95%CI:3.81–5.89) by LA; post-vaccination estimates were 1.67% (95%CI:1.21–2.13%) by LA, 1.49% (95%CI:1.05–1.93%) by cobas, and 1.63% (95%CI:1.17–2.08%) for cobas and LA testing of non-16/18 cobas positives (cobas/LA). Age-standardised pre-vaccination oncogenic HPV prevalence was 15.70% (95%CI:13.79–17.60%) by LA; post-vaccination estimates were 9.06% (95%CI:8.02–10.09%) by LA, 8.47% (95%CI:7.47–9.47%) by cobas and cobas/LA. Standardised rate ratios between post-vs. pre-vaccination rates were significantly different for HPV16/18, non-16/18 HPV and oncogenic HPV: 0.34 (95%CI:0.23–0.50), 0.68 (95%CI:0.55–0.84) and 0.58 (95%CI:0.48–0.69), respectively. Additional strategies (LA for all cobas positives; combined cobas and LA results on all samples) had similar results. If a single method is applied consistently, it will provide important data on relative changes in HPV prevalence following vaccination.http://www.sciencedirect.com/science/article/pii/S2666679023000022HPV-Based screeningCobas 4800Linear arraySurveillanceHPV vaccinationPrevalence |
| spellingShingle | Louiza S. Velentzis David Hawkes Michael Caruana Julia ML. Brotherton Megan A. Smith Lara Roeske Khurram A. Karim Suzanne M. Garland C. David Wrede Jeffery Tan Cosette Wheeler Philip E. Castle Marion Saville Karen Canfell Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening Tumour Virus Research HPV-Based screening Cobas 4800 Linear array Surveillance HPV vaccination Prevalence |
| title | Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening |
| title_full | Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening |
| title_fullStr | Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening |
| title_full_unstemmed | Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening |
| title_short | Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening |
| title_sort | exploring monitoring strategies for population surveillance of hpv vaccine impact using primary hpv screening |
| topic | HPV-Based screening Cobas 4800 Linear array Surveillance HPV vaccination Prevalence |
| url | http://www.sciencedirect.com/science/article/pii/S2666679023000022 |
| work_keys_str_mv | AT louizasvelentzis exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT davidhawkes exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT michaelcaruana exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT juliamlbrotherton exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT meganasmith exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT lararoeske exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT khurramakarim exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT suzannemgarland exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT cdavidwrede exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT jefferytan exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT cosettewheeler exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT philipecastle exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT marionsaville exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening AT karencanfell exploringmonitoringstrategiesforpopulationsurveillanceofhpvvaccineimpactusingprimaryhpvscreening |